Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 23, 2017

DrugPatentWatch Database Preview

FENTANYL-25 Drug Profile

« Back to Dashboard

Which patents cover Fentanyl-25, and when can generics launch?

Fentanyl-25 is a drug marketed by Actavis Labs Ut Inc, Aveva, Lavipharm Labs, Mallinckrodt Inc, Mylan Technologies, Mayne Pharma, Noven, and 3m Drug Delivery. and is included in eight NDAs.

The generic ingredient in FENTANYL-25 is fentanyl. There are thirty-one drug master file entries for this compound. Twenty-three suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the fentanyl profile page.

Summary for Tradename: FENTANYL-25

Patents:0
Applicants:8
NDAs:8
Suppliers / Packagers: see list19
Bulk Api Vendors: see list20
Clinical Trials: see list348
Patent Applications: see list5,546
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FENTANYL-25 at DailyMed

Pharmacology for Tradename: FENTANYL-25

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Ut Inc
FENTANYL-25
fentanyl
FILM, EXTENDED RELEASE;TRANSDERMAL076709-001Aug 20, 2007ABRXNoNo► Subscribe► Subscribe
Noven
FENTANYL-25
fentanyl
FILM, EXTENDED RELEASE;TRANSDERMAL077775-001Oct 16, 2009DISCNNoNo► Subscribe► Subscribe
Mallinckrodt Inc
FENTANYL-25
fentanyl
FILM, EXTENDED RELEASE;TRANSDERMAL077154-001Feb 9, 2011ABRXNoNo► Subscribe► Subscribe
3m Drug Delivery
FENTANYL-25
fentanyl
FILM, EXTENDED RELEASE;TRANSDERMAL202097-002Nov 4, 2016ABRXNoNo► Subscribe► Subscribe
Aveva
FENTANYL-25
fentanyl
FILM, EXTENDED RELEASE;TRANSDERMAL077449-001Oct 20, 2008ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Formulary management
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot